

# Peter Barany

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/718567/publications.pdf>

Version: 2024-02-01

221  
papers

14,348  
citations

18482

62  
h-index

22832

112  
g-index

230  
all docs

230  
docs citations

230  
times ranked

14455  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute kidney injury in infants with hypothermia-treated hypoxic ischaemic encephalopathy: An observational population-based study. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2022, 111, 86-92.	1.5	13
2	Use of nephrotoxic medications in adults with chronic kidney disease in Swedish and US routine care. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 442-451.	2.9	29
3	Epidemiology of Aortic Stenosis/Aortic Valve Replacement (from the Nationwide Swedish Renal) <i>Tj ETQq1 1 0.784314 rgBT /Qverlock</i>	1.6	6
4	Longitudinal genome-wide DNA methylation changes in response to kidney failure replacement therapy. <i>Scientific Reports</i> , 2022, 12, 470.	3.3	11
5	Association of Longitudinal High-Sensitivity Troponin T With Mortality in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 327-336.	2.8	5
6	Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2474-2486.	0.7	5
7	Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins. <i>Scientific Reports</i> , 2022, 12, 4414.	3.3	20
8	Cardiac biomarkers in pediatric CKD—a prospective follow-up study. <i>Pediatric Nephrology</i> , 2022, 37, 3165-3175.	1.7	1
9	Angiotensin-converting enzyme 2 and transmembrane protease serine 2 in female and male patients with end-stage kidney disease. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13786.	3.4	2
10	Sparing effect of peritoneal dialysis vs hemodialysis on BMD changes and its impact on mortality. <i>Journal of Bone and Mineral Metabolism</i> , 2021, 39, 260-269.	2.7	6
11	Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2213-2220.	2.9	31
12	Functional vitamin K insufficiency, vascular calcification and mortality in advanced chronic kidney disease: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0247623.	2.5	14
13	Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1780-1788.	2.9	4
14	High-sensitivity troponins in dialysis patients: variation and prognostic value. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1789-1797.	2.9	9
15	Muscle Abnormalities with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1613-1614.	4.5	0
16	Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1202-1211.	0.7	20
17	Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1518-1526.	0.7	62
18	Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREATinine Measurement project. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1908-1915.	0.7	14

#	ARTICLE	IF	CITATIONS
19	Bone mineral density at different sites and 5 years mortality in end-stage renal disease patients: A cohort study. <i>Bone</i> , 2020, 130, 115075.	2.9	20
20	Pediatric transplantation in Europe during the COVID-19 pandemic: Early impact on activity and healthcare. <i>Clinical Transplantation</i> , 2020, 34, e14063.	1.6	38
21	Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2059-2072.	0.7	28
22	Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 821-827.	2.9	29
23	Copeptin is independently associated with vascular calcification in chronic kidney disease stage 5. <i>BMC Nephrology</i> , 2020, 21, 43.	1.8	9
24	Association between reduced kidney function and incident hypoglycaemia in people with diabetes: The Stockholm Creatinine Measurements (SCREAM) project. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1425-1435.	4.4	8
25	Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1534-1541.	0.7	40
26	Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, F1122-F1131.	2.7	44
27	Serum 8-hydroxydeoxyguanosine, a marker of oxidative DNA damage, is associated with mortality independent of inflammation in chronic kidney disease. <i>European Journal of Internal Medicine</i> , 2019, 68, 60-65.	2.2	25
28	Health-related quality of life as predictor of mortality in end-stage renal disease patients: an observational study. <i>BMC Nephrology</i> , 2019, 20, 144.	1.8	33
29	Estimated Glomerular Filtration Rate and the Risk of Cancer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 530-539.	4.5	46
30	Albuminuria as a Predictor of Cardiovascular Outcomes in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2019, 8, e010546.	3.7	25
31	Differences in association of lower bone mineral density with higher coronary calcification in female and male end-stage renal disease patients. <i>BMC Nephrology</i> , 2019, 20, 59.	1.8	8
32	Causes of death across categories of estimated glomerular filtration rate: The Stockholm CREAtinine Measurements (SCREAM) project. <i>PLoS ONE</i> , 2019, 14, e0209440.	2.5	8
33	Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2051-2057.	0.7	15
34	Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. <i>Journal of Nephrology</i> , 2019, 32, 111-119.	2.0	42
35	Skin autofluorescence, arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 442-448.	0.7	25
36	Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1217-1226.	7.1	116

#	ARTICLE	IF	CITATIONS
37	Lung Dysfunction and Mortality in Patients with Chronic Kidney Disease. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 522-535.	2.0	33
38	Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. <i>Scientific Reports</i> , 2018, 8, 2103.	3.3	19
39	Lower serum calcium is independently associated with CKD progression. <i>Scientific Reports</i> , 2018, 8, 5148.	3.3	24
40	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. <i>European Heart Journal</i> , 2018, 39, 1535-1542.	2.2	218
41	Do metabolic derangements in end-stage polycystic kidney disease differ versus other primary kidney diseases?. <i>Nephrology</i> , 2018, 23, 31-36.	1.6	2
42	The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease—a prospective cohort study. <i>Pediatric Nephrology</i> , 2018, 33, 147-157.	1.7	17
43	SP298 HIGHER MEAN CORPUSCULAR VOLUME ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i444-i444.	0.7	0
44	FP336 HIGHER NEUTROPHIL TO LYMPHOCYTE RATIO ASSOCIATES WITH POOR CLINICAL OUTCOME IN CKD5 PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i144-i145.	0.7	0
45	SP330 AEGFR AND THE RISK OF CANCER: THE STOCKHOLM CREATININE MEASUREMENTS (SCREAM) PROJECT. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i455-i455.	0.7	0
46	Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study. <i>Nephron</i> , 2018, 140, 249-256.	1.8	8
47	SP323 HIGH FIBRINOGEN LEVELS ARE INDEPENDENTLY ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD). <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i452-i452.	0.7	0
48	Restrictive lung disorder is common in patients with kidney failure and associates with protein-energy wasting, inflammation and cardiovascular disease. <i>PLoS ONE</i> , 2018, 13, e0195585.	2.5	23
49	Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1314-1320.	4.5	45
50	The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease. <i>PLoS ONE</i> , 2018, 13, e0190410.	2.5	91
51	Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw328.	0.7	9
52	Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. <i>Journal of Nephrology</i> , 2017, 30, 255-262.	2.0	27
53	Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	57
54	Bone mineral density of extremities is associated with coronary calcification and biopsy-verified vascular calcification in living-donor renal transplant recipients. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 536-543.	2.7	8

#	ARTICLE	IF	CITATIONS
55	Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. <i>Kidney International</i> , 2017, 91, 244-251.	5.2	104
56	Does statins promote vascular calcification in chronic kidney disease?. <i>European Journal of Clinical Investigation</i> , 2017, 47, 137-148.	3.4	62
57	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 718-728.	11.4	110
58	eGFR and the Risk of Community-Acquired Infections. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1399-1408.	4.5	52
59	Plasma Beta-Trace Protein as a Marker of Residual Renal Function: The Effect of Different Hemodialysis Modalities and Intra-Individual Variability over Time. <i>Kidney and Blood Pressure Research</i> , 2017, 42, 877-885.	2.0	8
60	Clinical global assessment of nutritional status as predictor of mortality in chronic kidney disease patients. <i>PLoS ONE</i> , 2017, 12, e0186659.	2.5	60
61	CDKN2A/p16INK4a expression is associated with vascular progeria in chronic kidney disease. <i>Aging</i> , 2017, 9, 494-507.	3.1	52
62	SP242GLOMERULAR FILTRATION RATE ESTIMATION USING BETA TRACE PROTEIN: EXTERNAL VALIDATION OF THREE EQUATIONS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i167-i167.	0.7	0
63	SP286PLASMA BETA TRACE PROTEIN PREDICTS MORTALITY IN CKD: RELATION WITH ENDOTHELIAL DYSFUNCTION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i183-i184.	0.7	0
64	SP306PREVALENCE, DIAGNOSIS AND NEPHROLOGY CARE OF CKD IN THE REGION OF STOCKHOLM. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i191-i192.	0.7	0
65	Dialysis modality and nutritional status are associated with variability of inflammatory markers. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1320-1327.	0.7	42
66	Peritoneal dialysis impairs nitric oxide homeostasis and may predispose infants with low systolic blood pressure to cerebral ischemia. <i>Nitric Oxide - Biology and Chemistry</i> , 2016, 58, 1-9.	2.7	8
67	Assessing longitudinal trends in cardiac function among pediatric patients with chronic kidney disease. <i>Pediatric Nephrology</i> , 2016, 31, 1485-1497.	1.7	5
68	The Stockholm CREAAtinine Measurements (SCREAM) project: protocol overview and regional representativeness. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 119-127.	2.9	74
69	Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2016, 36, 269-276.	2.3	11
70	Vertebral bone density associates with coronary artery calcification and is an independent predictor of poor outcome in end-stage renal disease patients. <i>Bone</i> , 2016, 92, 50-57.	2.9	42
71	Prevalence and recognition of chronic kidney disease in Stockholm healthcare. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2086-2094.	0.7	101
72	Increased Telomere Attrition After Renal Transplantation – Impact of Antimetabolite Therapy. <i>Transplantation Direct</i> , 2016, 2, e116.	1.6	16

#	ARTICLE	IF	CITATIONS
73	Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1163-1172.	4.5	133
74	Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0141738.	2.5	241
75	Plasma Pentosidine and Its Association with Mortality in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0163826.	2.5	34
76	Endostatin, Cathepsin S, and Cathepsin L, and Their Association with Inflammatory Markers and Mortality in Patients Undergoing Hemodialysis. <i>Blood Purification</i> , 2015, 39, 259-265.	1.8	15
77	Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients. <i>Journal of Nephrology</i> , 2015, 28, 503-510.	2.0	50
78	Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 84-91.	0.7	52
79	Oxidative Dna Damage and Mortality in Hemodialysis and Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 206-215.	2.3	37
80	Plasma nitrate/nitrite removal by peritoneal dialysis might predispose infants with low blood pressure to cerebral ischaemia. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 215-218.	2.9	9
81	Serum hepatocyte growth factor is associated with truncal fat mass and increased mortality in chronic kidney disease stage 5 patients with protein-energy wasting. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 274-282.	0.7	10
82	High Levels of Soluble Tumor Necrosis Factor Receptors 1 and 2 and Their Association with Mortality in Patients Undergoing Hemodialysis. <i>CardioRenal Medicine</i> , 2015, 5, 89-95.	1.9	15
83	Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. <i>Kidney International</i> , 2015, 88, 1356-1364.	5.2	102
84	Increased Levels of Modified Advanced Oxidation Protein Products are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 460-470.	2.3	19
85	Associations between Thyroid Hormones, Calcification Inhibitor Levels and Vascular Calcification in End-Stage Renal Disease. <i>PLoS ONE</i> , 2015, 10, e0132353.	2.5	31
86	Validation of a competitive ELISA assay for the quantification of human serum hepcidin. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 652-8.	1.2	12
87	Selection of Genetic and Phenotypic Features Associated with Inflammatory Status of Patients on Dialysis Using Relaxed Linear Separability Method. <i>PLoS ONE</i> , 2014, 9, e86630.	2.5	4
88	IGF-1 and Survival in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 120-127.	4.5	34
89	Delta-He: a novel marker of inflammation predicting mortality and ESA response in peritoneal dialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 275-281.	2.9	10
90	Determinants of N-Terminal Pro-Brain Natriuretic Peptide Variation in Hemodialysis Patients and Prediction of Survival. <i>Blood Purification</i> , 2014, 37, 138-145.	1.8	7

#	ARTICLE	IF	CITATIONS
91	Systematic conversion to generic tacrolimus in stable kidney transplant recipients. CKJ: Clinical Kidney Journal, 2014, 7, 151-155.	2.9	25
92	Comparative Associations of Muscle Mass and Muscle Strength with Mortality in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1720-1728.	4.5	386
93	Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients. CKJ: Clinical Kidney Journal, 2014, 7, 373-379.	2.9	12
94	Subclinical Atherosclerosis, Endothelial Function, and Serum Inflammatory Markers in Chronic Kidney Disease Stages 3 to 4. Angiology, 2014, 65, 443-449.	1.8	16
95	Left ventricular diastolic dysfunction by tissue Doppler echocardiography in pediatric chronic kidney disease. Pediatric Nephrology, 2013, 28, 2003-2013.	1.7	32
96	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.7	628
97	Clinical determinants and mortality predictability of stearylâ€œC</scp>A</scp> desaturaseâ€œ activity indices in dialysis patients. Journal of Internal Medicine, 2013, 273, 263-272.	6.0	14
98	Self-Rated Appetite as a Predictor of Mortality in Patients With Stage 5 Chronic Kidney Disease. , 2013, 23, 106-113.		19
99	Letter to the Editor: BÃ¼ny and traumatic brain injury. Journal of Neurosurgery, 2013, 118, 908-912.	1.6	0
100	Determinants of Fibroblast Growth Factor-23 and Parathyroid Hormone Variability in Dialysis Patients. American Journal of Nephrology, 2013, 37, 462-471.	3.1	9
101	Subclinical versus overt obesity in dialysis patients: more than meets the eye. Nephrology Dialysis Transplantation, 2013, 28, iv175-iv181.	0.7	32
102	Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis?. Journal of Internal Medicine, 2013, 274, 584-593.	6.0	34
103	Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality. Clinical and Experimental Immunology, 2013, 174, 441-448.	2.6	5
104	Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2356-2363.	0.7	39
105	Obesity in children with end-stage renal disease. Nature Reviews Nephrology, 2013, 9, 707-708.	9.6	4
106	Determinants and survival implications of low bone mineral density in end-stage renal disease patients. Journal of Nephrology, 2013, 26, 485-494.	2.0	27
107	Can cardiovascular risk in dialysis patients be decreased?. Nature Reviews Nephrology, 2012, 8, 72-74.	9.6	6
108	Hypogonadism in Males with Chronic Kidney Disease: Another Cause of Resistance to Erythropoiesis-Stimulating Agents?. Contributions To Nephrology, 2012, 178, 35-39.	1.1	6



#	ARTICLE	IF	CITATIONS
109	The enigma of decreased creatinine generation in acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3973-3974.	0.7	12
110	Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 709-715.	0.7	74
111	Baseline Levels and Trimestral Variation of Triiodothyronine and Thyroxine and Their Association with Mortality in Maintenance Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 131-138.	4.5	54
112	Pentraxin 3, a Sensitive Early Marker of Hemodialysis-Induced Inflammation. <i>Blood Purification</i> , 2012, 34, 290-297.	1.8	21
113	Serum Albumin as Predictor of Nutritional Status in Patients with ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1446-1453.	4.5	138
114	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 70-75.	0.7	96
115	Plasma Fatty Acids in Chronic Kidney Disease: Nervonic Acid Predicts Mortality. , 2012, 22, 277-283.		26
116	Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3615-3620.	0.7	47
117	Screening for anti-factor B autoantibody in a patient with acute renal injury due to dense deposit disease. <i>Clinical Nephrology</i> , 2012, 77, 85-86.	0.7	0
118	Influence of Erythropoiesis-Stimulating Agents on Glycated Hemoglobin in Nondiabetic Kidney Diseases at the Start of Dialysis. <i>American Journal of Nephrology</i> , 2011, 33, 17-24.	3.1	5
119	Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor- $\alpha$ are similarly associated with survival in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1313-1318.	0.7	70
120	Circulating Follistatin in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1001-1008.	4.5	37
121	Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 184-190.	0.7	144
122	Inverse Relationship between the Inflammatory Marker Pentraxin-3, Fat Body Mass, and Abdominal Obesity in End-Stage Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2785-2791.	4.5	47
123	Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. <i>Kidney International</i> , 2011, 79, 749-756.	5.2	60
124	New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3237-3242.	0.7	95
125	Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. <i>Journal of Nephrology</i> , 2011, 24, 589-596.	2.0	44
126	Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 562-568.	0.7	116



#	ARTICLE	IF	CITATIONS
127	Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology</i> : CJASN, 2010, 5, 2213-2219.	4.5	83
128	Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 901-906.	0.7	50
129	Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3033-3038.	0.7	69
130	Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3717-3723.	0.7	15
131	Clinical importance of an elevated circulating chemerin level in incident dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 4017-4023.	0.7	40
132	Elevated Serum Macrophage Migration Inhibitory Factor (MIF) Concentrations in Chronic Kidney Disease (CKD) Are Associated with Markers of Oxidative Stress and Endothelial Activation. <i>Molecular Medicine</i> , 2009, 15, 70-75.	4.4	50
133	Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients. <i>Journal of the American Society of Nephrology</i> : JASN, 2009, 20, 613-620.	6.1	167
134	Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology</i> : CJASN, 2009, 4, 110-118.	4.5	106
135	Serum Retinol-Binding Protein Concentration and Its Association with Components of the Uremic Metabolic Syndrome in Nondiabetic Patients with Chronic Kidney Disease Stage 5. <i>American Journal of Nephrology</i> , 2009, 29, 447-453.	3.1	17
136	N-Terminal Pro-Brain Natriuretic Peptide Independently Predicts Protein Energy Wasting and Is Associated with All-Cause Mortality in Prevalent HD Patients. <i>American Journal of Nephrology</i> , 2009, 29, 516-523.	3.1	22
137	Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3454-3460.	0.7	24
138	Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3468-3473.	0.7	24
139	Comorbidity and Acute Clinical Events as Determinants of C-Reactive Protein Variation in Hemodialysis Patients: Implications for Patient Survival. <i>American Journal of Kidney Diseases</i> , 2009, 53, 1024-1033.	1.9	111
140	Temporal discrepancies in the association between the apoB/apoA $\epsilon$ ratio and mortality in incident dialysis patients. <i>Journal of Internal Medicine</i> , 2009, 265, 708-716.	6.0	19
141	Variations in graft and patient survival after kidney transplantation in Sweden: caveats in interpretation of center effects when benchmarking. <i>Transplant International</i> , 2009, 22, 1051-1057.	1.6	6
142	Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2009, 54, 1072-1080.	1.9	75
143	Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. <i>Journal of Nephrology</i> , 2009, 22, 774-82.	2.0	29
144	Low serum fetuin $\epsilon$ A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. <i>European Journal of Clinical Investigation</i> , 2008, 38, 804-811.	3.4	51

#	ARTICLE	IF	CITATIONS
145	Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. <i>Journal of Internal Medicine</i> , 2008, 263, 302-312.	6.0	165
146	Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. <i>Clinical Nutrition</i> , 2008, 27, 557-564.	5.0	230
147	Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. <i>Clinica Chimica Acta</i> , 2008, 395, 106-110.	1.1	58
148	Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 976-985.	4.5	103
149	Bone Mineral Density in End-Stage Renal Disease Patients: Association with Wasting, Cardiovascular Disease and Mortality. <i>Blood Purification</i> , 2008, 26, 284-290.	1.8	25
150	Hyperinsulinemia and Insulin Resistance, Early Cardiovascular Risk Factors in Children with Chronic Kidney Disease. <i>Blood Purification</i> , 2008, 26, 518-525.	1.8	13
151	Lipoprotein Lipase 1595 C/G and Hepatic Lipase 480 C/T Polymorphisms Impact on Lipid Profile in Incident Dialysis Patients. <i>Blood Purification</i> , 2008, 26, 555-560.	1.8	2
152	Is Fetuin-A/Î±2-Heremans-Schmid Glycoprotein Associated with the Metabolic Syndrome in Patients with Chronic Kidney Disease?. <i>American Journal of Nephrology</i> , 2008, 28, 669-676.	3.1	30
153	The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 397-405.	0.5	55
154	Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 1860-1866.	4.7	228
155	High Mobility Group Box Protein-1 Correlates with Renal Function in Chronic Kidney Disease (CKD). <i>Molecular Medicine</i> , 2008, 14, 109-115.	4.4	92
156	Plasma Pentraxin 3 in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 889-897.	4.5	154
157	Association between oestrogen receptor A gene polymorphism and mortality in female end-stage renal disease patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2571-2577.	0.7	5
158	Influence of cytokine gene polymorphisms on erythropoietin dose requirements in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3586-3592.	0.7	12
159	Associations between the CYBA 242C/T and the MPO 463G/A Polymorphisms, Oxidative Stress and Cardiovascular Disease in Chronic Kidney Disease Patients. <i>Blood Purification</i> , 2007, 25, 210-218.	1.8	20
160	Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, iv10-iv18.	0.7	13
161	Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 695-701.	4.7	202
162	Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. <i>American Journal of Clinical Nutrition</i> , 2007, 86, 633-638.	4.7	246

#	ARTICLE	IF	CITATIONS
163	Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. <i>Clinica Chimica Acta</i> , 2007, 379, 87-94.	1.1	47
164	Impact of inflammation on epigenetic DNA methylation – a novel risk factor for cardiovascular disease?. <i>Journal of Internal Medicine</i> , 2007, 261, 488-499.	6.0	344
165	Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. <i>Journal of Internal Medicine</i> , 2007, 262, 690-701.	6.0	144
166	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Homocysteine – Lowering Is Not a Primary Target for Cardiovascular Disease Prevention in Chronic Kidney Disease Patients. <i>Seminars in Dialysis</i> , 2007, 20, 523-529.	1.3	18
167	Circulating Levels of Visfatin/Pre-B-Cell Colony-Enhancing Factor 1 in Relation to Genotype, GFR, Body Composition, and Survival in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2007, 49, 237-244.	1.9	109
168	Oral health and pro-inflammatory status in end-stage renal disease patients. <i>Oral Health &amp; Preventive Dentistry</i> , 2007, 5, 235-44.	0.5	14
169	Hyperhomocysteinemia, Malnutrition, and Inflammation in ESRD Patients. <i>Seminars in Nephrology</i> , 2006, 26, 14-19.	1.6	6
170	Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease?. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 718-726.	2.9	43
171	Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. <i>Kidney International</i> , 2006, 69, 596-604.	5.2	209
172	Serum Albumin, C-Reactive Protein, Interleukin 6, and Fetuin A as Predictors of Malnutrition, Cardiovascular Disease, and Mortality in Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 139-148.	1.9	442
173	J-Shaped Mortality Relationship for Uric Acid in CKD. <i>American Journal of Kidney Diseases</i> , 2006, 48, 761-771.	1.9	213
174	Changes in Fat Mass Correlate With Changes in Soluble sCD163, a Marker of Mature Macrophages, in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2006, 48, 916-925.	1.9	64
175	Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 125-132.	0.7	98
176	Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 196-202.	0.7	30
177	The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 209-217.	0.7	61
178	Statin Treatment and Diabetes Affect Myeloperoxidase Activity in Maintenance Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 281-287.	4.5	38
179	Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. <i>Kidney International</i> , 2005, 67, 2383-2392.	5.2	274
180	Body Fat Mass and Serum Leptin Levels Influence Epoetin Sensitivity in Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2005, 46, 628-634.	1.9	78

#	ARTICLE	IF	CITATIONS
181	Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. <i>American Journal of Clinical Nutrition</i> , 2005, 82, 342-349.	4.7	60
182	Inflammation and resistance to erythropoiesis-stimulating agents—what do we know and what needs to be clarified?. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, viii2-viii7.	0.7	56
183	Is the efficacy of epoetin beta in anemic peritoneal dialysis patients maintained with fortnightly doses?. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 12-13.	2.0	0
184	Interleukin-1 Gene Cluster Polymorphisms Are Associated with Nutritional Status and Inflammation in Patients with End-Stage Renal Disease. <i>Blood Purification</i> , 2005, 23, 384-393.	1.8	21
185	Homocysteine in uraemia—a puzzling and conflicting story. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 16-21.	0.7	130
186	Peroxisome proliferator-activated receptor $\beta$ polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. <i>Atherosclerosis</i> , 2005, 182, 105-111.	0.8	29
187	Why Do Dialysis Patients Develop a Heart of Stone and Bone of China?. <i>Blood Purification</i> , 2005, 23, 203-210.	1.8	24
188	Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 288-293.	0.7	81
189	Foreword. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, ii1-ii1.	0.7	461
190	Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1823-1828.	0.7	40
191	Adiponectin in renal disease: Relationship to phenotype and genetic variation in the gene encoding adiponectin. <i>Kidney International</i> , 2004, 65, 274-281.	5.2	160
192	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. <i>American Journal of Kidney Diseases</i> , 2004, 44, 455-465.	1.9	38
193	SECTION I. Anaemia Evaluation. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, ii2-ii5.	0.7	8
194	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. <i>American Journal of Kidney Diseases</i> , 2004, 44, 455-465.	1.9	16
195	Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. <i>American Journal of Kidney Diseases</i> , 2004, 44, 455-65.	1.9	11
196	Varying intervals of subcutaneous epoetin alfa in hemodialysis patients. <i>Journal of Nephrology</i> , 2004, 17, 525-30.	2.0	5
197	Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: Influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. <i>American Journal of Kidney Diseases</i> , 2003, 41, S89-S95.	1.9	47
198	Associations between circulating inflammatory markers and residual renal function in CRF patients. <i>American Journal of Kidney Diseases</i> , 2003, 41, 1212-1218.	1.9	371

#	ARTICLE	IF	CITATIONS
199	A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. <i>Kidney International</i> , 2003, 63, S172-S176.	5.2	105
200	Plasma Pentosidine Is Associated with Inflammation and Malnutrition in End-Stage Renal Disease Patients Starting on Dialysis Therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1614-1622.	6.1	131
201	A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1266-1274.	0.7	166
202	Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1050-1056.	0.7	22
203	Accumulation of taurine in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 528-529.	0.7	29
204	Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1684-1688.	0.7	345
205	Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 32-37.	0.7	82
206	Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. <i>American Journal of Kidney Diseases</i> , 2002, 40, e22.1-e22.4.	1.9	63
207	Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. <i>American Journal of Kidney Diseases</i> , 2002, 40, 480-488.	1.9	51
208	Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. <i>Kidney International</i> , 2002, 62, 2167-2175.	5.2	157
209	Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6?. <i>Kidney International</i> , 2002, 61, S103-S108.	5.2	159
210	Effect of 6 weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 580-584.	0.7	34
211	Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulphâ€hydryls before and after coâ€factor supplementation in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 102-110.	0.7	18
212	Hyperhomocysteinemia in Chronic Renal Failure Patients: Relation to Nutritional Status and Cardiovascular Disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 734-8.	2.3	39
213	Inflammation, serum Câ€reactive protein, and erythropoietin resistance. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 224-227.	0.7	91
214	Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. <i>Kidney International</i> , 2000, 57, 1727-1735.	5.2	177
215	Effects of High-Dose Folic Acid and Pyridoxine on Plasma and Erythrocyte Sulfur Amino Acids in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1287-1296.	6.1	53
216	Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure?. <i>Kidney International</i> , 1998, 53, 1430-1431.	5.2	23

#	ARTICLE	IF	CITATIONS
217	High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. American Journal of Kidney Diseases, 1997, 29, 565-568.	1.9	488
218	Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clinical Nephrology, 1997, 48, 1-8.	0.7	64
219	Endocrinology and Pd: Optimal Treatment of Anemia in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 1996, 16, 260-267.	2.3	18
220	Subcutaneous Epoetin Beta in Renal Anemia: An Open Multicenter Dose Titration Study of Patients on Continuous Peritoneal Dialysis. Peritoneal Dialysis International, 1995, 15, 54-60.	2.3	12
221	Immunological Aspects of Haemodialysis. BioDrugs, 1994, 1, 469-480.	0.7	1